Vincent Cottin1, Elisabeth Bel2, Paolo Bottero3, Klaus Dalhoff4, Marc Humbert5, Romain Lazor6, Renato A Sinico7, Pasupathy Sivasothy8, Michael E Wechsler9, Matthieu Groh10, Sylvain Marchand-Adam11, Chahéra Khouatra12, Benoit Wallaert13, Camille Taillé14, Philippe Delaval15, Jacques Cadranel16, Philippe Bonniaud17, Grégoire Prévot18, Sandrine Hirschi19, Anne Gondouin20, Bertrand Dunogué10, Gérard Chatté21, Christophe Briault22, Christian Pagnoux23, David Jayne24, Loïc Guillevin10, Jean-François Cordier12. 1. Hospices civils de Lyon, Hôpital Louis Pradel, Service de pneumologie - centre national de référence des maladies pulmonaire rares, Université de Lyon, Université Claude Bernard Lyon I, UCBL-INRA-ENVL-EPHE, UMR754, IFR128, Lyon, France. Electronic address: vincent.cottin@chu-lyon.fr. 2. Department of Respiratory Medicine, Academic Medical Center, PO Box 22660, 1100 DD Amsterdam, The Netherlands. 3. Allergy and Clinical Immunology Outpatient Clinic, Ospedale "G. Fornaroli" di Magenta, Azienda Ospedaliera di Legnano, Milan, Italy. 4. Medizinische Klinik III, Universitätsklinikum Schleswig Holstein, Campus Lübeck, Member of the German Center for Lung Research (DZL), D-23538, Lübeck, Germany. 5. CHU Bicêtre, service de pneumologie, 94270, Le Kremlin-Bicêtre, France. 6. Interstitial and rare lung disease Unit, Respiratory Medicine Department, Lausanne, University Hospital, Lausanne, Switzerland. 7. Department of Medicine and Surgery Università degli Studi di Milano - Bicocca (School of Medicine and Surgery), via Cadore, 48 - 20900 Monza (MB), Italy. 8. Department of Respiratory Medicine, Addenbrookes Hospital, Cambridge University Hospitals Foundation Trust, Hills Rd, Cambridge, United Kingdom CB3 9LG. 9. National Jewish Health, Denver, CO, USA, and University of Colorado, Aurora, CO. 10. Department of Internal Medicine, National Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, Assistance Publique Hôpitaux de Paris, Université Paris Descartes, Paris, France. 11. CHRU Tours, service de pneumologie et université Francois Rabelais, Tours, France. 12. Hospices civils de Lyon, Hôpital Louis Pradel, Service de pneumologie - centre national de référence des maladies pulmonaire rares, Université de Lyon, Université Claude Bernard Lyon I, UCBL-INRA-ENVL-EPHE, UMR754, IFR128, Lyon, France. 13. CHRU Lille, service de pneumologie, Lille, France. 14. INSERM U1152 ; Univ Paris Diderot, Sorbonne Paris Cité ; Assistance Publique- Hôpitaux de Paris, Hôpital Bichat, Service de Pneumologie A ; Département hospitalo-universitaire FIRE, Competence Center for Rare Pulmonary Diseases, 75018, Paris, France. 15. CHU Rennes, service de pneumologie, Rennes, France. 16. Chest Department and Expert Center for Rare Pulmonary Diseases. APHP Hôpital Tenon and P&M Curie University Paris 6, Paris, France. 17. Service de Pneumologie et Soins Intensifs Respiratoires, Centre, Hospitalier universitaire (CHU) François Mitterrand, Inserm U866, Université de Bourgogne, Faculté de Médecine et Pharmacie, Dijon, France; Dijon, 21079, France. 18. CHU de Toulouse, service de pneumologie, Toulouse, France. 19. Hôpitaux universitaires de Strasbourg, nouvel hôpital civil, service de pneumologie, centre de compétences des maladies pulmonaires rares, 1 place de l'hôpital, F-67000, Strasbourg, France. 20. CHU de Besançon, service de pneumologie, Besançon, France. 21. Centre de Pneumologie et Allergologie Respiratoire, Caluire et Cuire, France. 22. CHU de Grenoble, service de pneumologie, Grenoble, France. 23. Toronto, Canada. 24. Department of Medicine, University of Cambridge, UK.
Abstract
OBJECTIVE: To guide nosology and classification of patients with eosinophilic granulomatosis with polyangiitis (EGPA) based on phenotype and presence or absence of ANCA. METHODS: Organ manifestations and ANCA status were retrospectively analyzed based on the presence or not of predefined definite vasculitis features or surrogates of vasculitis in patients asthma, eosinophilia, and at least one systemic organ manifestation attributable to systemic disease. RESULTS: The study population included 157 patients (mean age 49.4±14.1), with a follow-up of 7.4±6.4years. Patients with ANCA (31%) more frequently had weight loss, myalgias, arthralgias, biopsy-proven vasculitis, glomerulonephritis on biopsy, hematuria, leukocytoclastic capillaritis and/or eosinophilic infiltration of arterial wall on biopsy, and other renal disease. A total of 41% of patients had definite vasculitis manifestations (37%) or strong surrogates of vasculitis (4%), of whom only 53% had ANCA. Mononeuritis multiplex was associated with systemic vasculitis (p=0.005) and with the presence of ANCA (p<0.001). Overall, 59% of patients had polyangiitis as defined by definite vasculitis, strong surrogate of vasculitis, mononeuritis multiplex, and/or ANCA with at least one systemic manifestation other than ENT or respiratory. Patients with polyangiitis had more systemic manifestations including arthralgias (p=0.02) and renal disease (p=0.024), had higher peripheral eosinophilia (p=0.027), and a trend towards less myocarditis (p=0.057). Using predefined criteria of vasculitis and surrogates of vasculitis, ANCA alone were found to be insufficient to categorise patients with vasculitis features. CONCLUSION: We suggest a revised nomenclature and definition for EGPA and a new proposed entity referred to as hypereosinophilic asthma with systemic (non vasculitic) manifestations.
OBJECTIVE: To guide nosology and classification of patients with eosinophilic granulomatosis with polyangiitis (EGPA) based on phenotype and presence or absence of ANCA. METHODS: Organ manifestations and ANCA status were retrospectively analyzed based on the presence or not of predefined definite vasculitis features or surrogates of vasculitis in patientsasthma, eosinophilia, and at least one systemic organ manifestation attributable to systemic disease. RESULTS: The study population included 157 patients (mean age 49.4±14.1), with a follow-up of 7.4±6.4years. Patients with ANCA (31%) more frequently had weight loss, myalgias, arthralgias, biopsy-proven vasculitis, glomerulonephritis on biopsy, hematuria, leukocytoclastic capillaritis and/or eosinophilic infiltration of arterial wall on biopsy, and other renal disease. A total of 41% of patients had definite vasculitis manifestations (37%) or strong surrogates of vasculitis (4%), of whom only 53% had ANCA. Mononeuritis multiplex was associated with systemic vasculitis (p=0.005) and with the presence of ANCA (p<0.001). Overall, 59% of patients had polyangiitis as defined by definite vasculitis, strong surrogate of vasculitis, mononeuritis multiplex, and/or ANCA with at least one systemic manifestation other than ENT or respiratory. Patients with polyangiitis had more systemic manifestations including arthralgias (p=0.02) and renal disease (p=0.024), had higher peripheral eosinophilia (p=0.027), and a trend towards less myocarditis (p=0.057). Using predefined criteria of vasculitis and surrogates of vasculitis, ANCA alone were found to be insufficient to categorise patients with vasculitis features. CONCLUSION: We suggest a revised nomenclature and definition for EGPA and a new proposed entity referred to as hypereosinophilic asthma with systemic (non vasculitic) manifestations.
Authors: Guillermo Carvajal Alegria; Pierre Gazeau; Sophie Hillion; Claire I Daïen; Divi Y K Cornec Journal: Clin Rev Allergy Immunol Date: 2017-10 Impact factor: 8.667
Authors: Irena Doubelt; David Cuthbertson; Simon Carette; Sharon A Chung; Lindsy J Forbess; Nader A Khalidi; Curry L Koening; Carol Langford; Carol A McAlear; Larry W Moreland; Paul A Monach; Philip Seo; Ulrich Specks; Robert F Spiera; Jason M Springer; Antoine G Sreih; Kenneth J Warrington; Peter A Merkel; Christian Pagnoux Journal: ACR Open Rheumatol Date: 2021-05-25